Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion: 2012-2024

Historic Depreciation and Depletion for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $28.2 million.

  • Amphastar Pharmaceuticals' Depreciation and Depletion rose 8.85% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year increase of 11.56%. This contributed to the annual value of $28.2 million for FY2024, which is 12.08% up from last year.
  • Amphastar Pharmaceuticals' Depreciation and Depletion amounted to $28.2 million in FY2024, which was up 12.08% from $25.2 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Depreciation and Depletion registered a high of $28.2 million during FY2024, and its lowest value of $20.5 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Depreciation and Depletion had a median value of $25.2 million in 2023 and averaged $25.8 million.
  • Data for Amphastar Pharmaceuticals' Depreciation and Depletion shows a peak YoY increased of 19.88% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Depreciation and Depletion stood at $20.5 million in 2020, then increased by 8.29% to $22.2 million in 2021, then increased by 7.27% to $23.8 million in 2022, then grew by 5.84% to $25.2 million in 2023, then rose by 12.08% to $28.2 million in 2024.